Save my name, email, and website in this browser for the next time I comment.
Graphical abstract for the article Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily published in the July edition (2014) of Haematologica.
Please send me info about:
Tips and Tricks to 'Visually' Succeed in Scientific Publishing
© 2019 somersault18:24. All Rights Reserved, somersault18:24